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This study concerns a 69-year-old female patient with a longstanding history of venous ulcerations on
both lower legs and multiple sensitivities, who developed eczematous lesions with the hydrocolloid
dressing Combiderm1 (Convatec Ltd., a Bristol-Myers Squibb division, Ickenham, Middlesex,
UK). Epicutaneous tests were positive to this dressing and to a modified colophonium derivative,
i.e. glyceryl rosinate, however not to the unmodified colophonium from the standard series. A review
of the literature showed several case reports about sensitization to similar hydrocolloids being
distributed under various brand names in different countries and which contain the pentaerythritol
ester of the hydrogenated rosin as the tackifying agent. Some of the patients described did, while
others did not, react to colophonium but only to a modified derivative. In our patient, the reaction to
glyceryl rosinate most probably represent cross-sensitivity with the modified colophonium derivative
used in Combiderm1, the presence (but not the exact nature) of which was showed by the company.
In patients where allergic contact dermatitis from hydrocolloid dressings is strongly suspected and
colophonium tests negatively, patch testing to modified colophonium derivatives should therefore be
performed. As the complete composition of wound dressings is most often unknown, we urgently
advocate legal requirements for labelling of those and in fact all medically used devices.
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Leg ulcers represent a chronic condition affecting
more than 1.7% of the population older than 65
years (1). Because healing is difficult to achieve,
these patients are exposed to many topical drugs
and dressings for long period of time. Sensitiza-
tion therefore occurs in these patients and
increases with duration of the ulcer (2). Over the
past years, because of their sophisticated compos-
ition, hydrocolloids dressing have been introduced
routinely in the treatment of various types of
wounds, which may be clean, granulating or
necrotic, or with low to moderate exudates. They
provide a moist environment, promoting autolytic
debridement, and stimulation of angiogenesis.
While these dressings may be more expensive, if
used correctly, they are cost-effective because they
have a longer wear time. However, long-term
application often leads to inflammation of the
skin in the immediate neighbourhood of the ulcer,
being an irritant dermatitis in many cases, but
sometimes also leads to contact sensitization.
Case Report
A 69-year-old female patient presented with a
longstanding history of severe venous insufficiency
and venous ulcerations on both lower legs, with
recurrent eczematous dermatitis. Patch tests had
already been carried out twice, both in the Leuven
Contact Allergy Unit, 23 years ago, and by a pri-
vate dermatologist, 2 years ago, and had showed
multiple sensitivities: para-phenylenediamine,para-
bens, wool alcohols, clioquinol, neomycin, nickel
sulfate, Myroxylon pereirae (balsam of Peru), fra-
grance mix, budesonide, phenoxyethanol, cetyl-
alcohol, nonoxynol, bacitracine, and benzocaine.
In August 2005, the patient again presented to
the Leuven outpatient Chronic Wound Clinic
because of an ulcer on the left lower leg of 6 month
duration. She had applied Duoderm1 hydro-
active bandage and later on Combiderm1 (both
from Convatec, a Bristol-Myers Squibb division,
UK), but the ulcer got worse, became weeping and
more painful. An allergic contact dermatitis was
suspected, and she was asked to apply the adhe-
sive part of both hydrocolloids to her forearms,
the adhesive part of the Combiderm1 clearly
producing an eczematous reaction 3 days later
(Fig. 1). Patch tests were again performed in
September 2005 with Combiderm1 (tested as is),
colophonium (Trolab, Reinbeck, Germany) as
present in the standard series and other allergens
possibly present in adhesives, such as polyethylene
glycol 400 20% aqua, acrylate components, and
modified colophonium (Table 1), i.e. glyceryl ros-
inate [20% petrolatum (pet.)] that was available to
us from Reckitt Benckiser (Massy, France) (3).
Positive reactions were obtained to this hydro-
colloid as well as to the modified colophonium
derivative (Fig. 2).
Convatec informed us that Combiderm1 con-
sists of 2 elements: a non-adhesive layer based on
polypropylene in contact with the wound (to
which the patient did not react positively) and
an adhesive part having a similar composition as
Duoderm extra thin1 (also from Convatec),
which contains the pentaerythritol ester of rosin
(Pentalyn1), a modified colophonium deriva-
tive that is not present in the regular Duoderm
(4) to which our patient had not reacted on her
forearm.
The ulcer was first treated with KMnO4 com-
presses (dilution 1/4000) and zinc oxide paste,
and compressive therapy was given. Because of
Fig. 1. Positive ‘use’ test with Combiderm1 (reading at 3 days).
Table 1. Patch tests results
Patch tests D2 D4
Combiderm1 (as is) þ þ
Colophonium 20% pet.  
Modified colophonium
(glyceryl rosinate, 20% pet.)
þ þ
Polyethylene glycol 400, 20% aqua  
Acrylate components:
methyl methacrylate 2% pet.,
2-hydroxyethylacrylate 2% pet.,
hydroxyethylmethacrylate 2% pet.,
ethyleneglycol dimethacrylate 2% pet.,
and epoxy-acrylate 0.5% pet.
(all from Chemotechnique, Malmo, Sweden)
 
Pet., petrolatum; D, days.
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Staphylococcus aureus infection, she was given
antibiotic therapy with erythromycin ethyl suc-
cinate (Erythroforte1; Abbott, Ottignies, Belgium).
The dermatitis cleared, and the ulcer became better
but did not heal completely before May 2006.
Discussion
Investigations on the sensitizing potential of mod-
ern wound dressings are few and focus only on sin-
gle sensitizing agents. In a study by Gallenkemper
et al. (5), 20 different wound dressings were tested
in 36 patients with chronic venous insufficiency
and positive reactions were observed in 3 of them,
i.e. 8.3%. All the cases were related to propylene
glycol as an ingredient of hydrogels. They did not
detect sensitization to hydrocolloids, alginates or
polyurethane foams. Later on, Tavadia et al. (6)
and Machet et al. (2) have obtained similar results
and observed very low rates of sensitivity to the
newer dressings, with the exception of hydrogels.
They did observe positive reactions to colopho-
nium; however, they did not test modified colo-
phonium derivatives.
Nevertheless, a review of the literature shows
several isolated case reports of sensitization to
similar hydrocolloids being produced by the same
manufacturer but distributed under various brand
names in different countries. This concerns case
reports about Duoderm E1 or CGF1 (3 cases)
(4) and 1 case to Varihesive1 (Duoderm E) (7), all
containing the pentaerythritol ester of the hydro-
genated rosin (Pentalyn1) as the tackifying agent.
In these cases, positive patch test reactions were
observed to the dressings as well as to colopho-
nium. However, none of the patients was tested to
the ester of hydrogenated rosin (modified colo-
phonium), but the authors assumed that the
patients became sensitized to this compound, in
view of their concomitant reaction to colopho-
nium. Mallon and Powell (8) identified
Pentalyn1, i.e. the pentaerythritol ester of hydro-
genated rosin (diluted 10% and 20% pet.), as the
responsible allergen in 2 patients with allergic con-
tact dermatitis from Granuflex E1 that also
reacted positively on patch testing. They also
obtained positive reactions to colophonium and
ester gum resin (glycerol ester). Schliz et al. (9) per-
formed patch tests with Varihesive E1 and
Comfeel1 (Coloplast BV, Peterborough, UK) in
41 consecutive patients with leg ulcers, 8 of whom
reacted to one or both dressings; they identified the
contact allergen Pentalyn1 in 1 patient and
a derivative of polyisobutylene in another patient.
In the other 6 cases that patch tested positively to
hydrocolloid dressings, the authors could not iden-
tify the responsible allergen. Mollin (10) tested 25
consecutive patients hospitalized for chronic
venous ulcers and found 13 patients with positive
patch test reactions to various types ofDuoderm1
dressings: among them, 10 reacted toDuodermE1
and 8 were allergic to Pentalyn1. However, they
did not address the question of cross-sensitization
with unmodified colophonium nor mentioned the
allergen responsible in the other cases.
Some authors have reported cases in which, as
in our patient, in contrast to a positive test to
a modified colophonium derivative, unmodified
colophonium did not react (11, 12). Downs et al.
(11) described 7 patients with allergic contact
dermatitis from Granuflex1: patch testing was
positive to unmodified colophonium and the
hydrogenated pentaerythritol-esterified gum rosin
in 3 patients but positive only to the latter in
another 2 patients. In 1270 patients with leg ulcer
tested, by Salim and Shaw (12), with both colo-
phonium and ester gum rosin, positive reactions
to both colophonium and ester gum rosin were
observed in 31% of the patients and to colopho-
nium alone in 29% but to ester gum rosin alone in
40% of the patients.
Fig. 2. Positive patch tests to both Combiderm1 and glyc-
eryl rosinate (modified colophonium).
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Colophonium (rosin) derived from pine resin,
tall oil and stump extractives. It is used as is or
in chemically modified forms: hydrogenated, dis-
proportionated, esterified, polymerized, as salt, or
reaction products with maleic anhydride or form-
aldehyde. The pentaerythritol rosinate is an ester
gum derived from rosin (mostly abietic acid) and
pentaerythritol (13). Modifications of colopho-
nium form new potent allergens not found in
unmodified colophony. Hausen et al. (14) per-
formed patch testing with 6 types of unmodified
colophonium and 12 types of modified colopho-
nium products and found that 17 of 137 patients
did not react to the unmodified colophonium but
responded to 1 or more of the modified products.
The hydrogenated pentaerythritol rosinate is
likely to be a complex blend of chemicals because
hydrogenation of gum rosinwill produce amixture
rich in dihydro-, tetrahydro-, and dehydroabietic
acids (15). These modifications of gum rosin do
not appear to alter its allergenicity after penta-
erythritol esterification because cross-reactivity
with fully hydrogenated pentaerythritol rosinate
is preserved.
In our case, the patch testing was positive to the
glyceryl rosinate, but we failed to identify the exact
nature of the ester gum derivative present in
Combiderm1. Major allergens have been identi-
fied and synthesized fromglycerol-modified, fuma-
ric acid-modified, and maleic anhydride-modified
gum rosins that do not cross-react with colopho-
nium (16). This explains why unmodified colopho-
nium (in the standard series) is often negative in
patients sensitized by modified rosin derivatives,
the latter being probably more potent sensitizers.
Due to their resistance to oxidation and dis-
colouration (16), colophonium derivatives are
used as ‘tackifiers’ in natural and synthetic rubber,
in adhesives for lamination of paper and in
several other protective coating compositions. In
medicine, besides hydrocolloids, they are found in
adhesive tapes, plasters, bandages and medicated
creams and ointments. Unfortunately, these tacki-
fiers – as all other ingredients – are not declared
ingredients of medical devices including wound
dressing.
Conclusion
As in several literature reports, this case illustrates
that unmodified gum rosin or colophonium 20%
pet., as present in the European standard series,
often fails to detect contact allergy to hydrocol-
loids and that patch testing should include modi-
fied colophonium derivatives such as glycerol
esters present in them. Moreover, in the Leuven
Contact Allergy Unit, we already did observe sev-
eral patients with leg ulcer suspected to suffer
from allergic contact dermatitis when hydrocol-
loids were used on damaged skin but for whom
patch testing with the dressing itself failed to pro-
duce a positive reaction on normal skin. As the
complete composition is in most cases not known,
it is not possible to identify the responsible aller-
gens nor to give advice for safer alternatives.
Therefore, we advocate that medical devices,
including wound dressings, bandages, adhesives,
etc., that are used medically and applied on dam-
aged skin, should be labelled with their complete
qualitative composition (as is the case for all cos-
metic products, which are applied to normal skin!).
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